Sanara MedTech Inc. (SMTI)

Market Cap	154.28M -47.5%
Revenue (ttm)	103.12M +19.0%
Net Income	-37.56M
EPS	-4.36
Shares Out	9.17M
PE Ratio	n/a
Forward PE	105.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,202
Open	17.13
Previous Close	17.19
Day's Range	16.68 - 17.49
52-Week Range	16.05 - 35.95
Beta	1.10
Analysts	Strong Buy
Price Target	36.00 (+113.9%)
Earnings Date	May 13, 2026

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2025, Sanara MedTech's revenue was $103.12 million, an increase of 18.97% compared to the previous year's $86.67 million. Losses were -$37.56 million, 288.7% more than in 2024.

Analyst Summary

According to one analyst, the rating for SMTI stock is "Strong Buy" and the 12-month stock price target is $36.0.

Price Target

$36.0

(113.90% upside)

Analyst Consensus: Strong Buy